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Over the past 15 years, genome-wide association studies (GWASs) have
enabled the systematic identification of genetic loci associated with traits
and diseases. However, due to resolution issues and methodological
limitations, the true causal variants and genes associated with traits
remain difficult to identify. In this post-GWAS era, many biological and
computational fine-mapping approaches now aim to solve these issues.
Here, we review fine-mapping and gene prioritization approaches that,
when combined, will improve the understanding of the underlying
mechanisms of complex traits and diseases. Fine-mapping of genetic
variants has become increasingly sophisticated: initially, variants were
simply overlapped with functional elements, but now the impact of variants
on regulatory activity and direct variant-gene 3D interactions can be
identified. Moreover, gene manipulation by CRISPR/Cas9, the identification
of expression quantitative trait loci and the use of co-expression networks
have all increased our understanding of the genes and pathways affected
by GWAS loci. However, despite this progress, limitations including
the lack of cell-type- and disease-specific data and the ever-increasing
complexity of polygenic models of traits pose serious challenges. Indeed,
the combination of fine-mapping and gene prioritization by statistical,
functional and population-based strategies will be necessary to truly
understand how GWAS loci contribute to complex traits and diseases.1. Introduction
Most, if not all, phenotypic traits and diseases have a genetic component that
influences their development, susceptibility or characteristics. Which genetic
regions (loci) are linked to phenotypic traits has largely been determined
by genome-wide association studies (GWASs) (figure 1a). GWASs compare
and associate millions of relatively common genetic variants, usually single-
nucleotide polymorphisms (SNPs), between a baseline (healthy) population
and one with a trait of interest such as type 1 diabetes [1], coeliac disease [2]
or height [3]. The trait-associated genetic loci obtained by GWASs are
marked by specific variants referred to as marker or top variants. Each
marker-variant signifies a haplotype containing many nearby variants that
are in high linkage disequilibrium (LD), indicating that they are most likely
to be inherited together [4] (figure 1b). Over 4000 GWASs have been published
since 2002 [5], yielding almost 150 000 marker variant associations to hundreds
of traits [6]. However, despite the method’s great initial promise, GWASs have
not provided immediate insights into the underlying biological mechanisms of
each trait due to two major complicating factors.
Firstly, GWASs cannot distinguish the marker-variant signal from that of
the other varaints that are in high LD. Over 95% of the variants in high LD














































Figure 1. Outline of the current post-GWAS workflow. (a) First, the correct context needs to be identified for the trait under study. (b) Subsequently, causal variants
can be fine-mapped to better understand the fundamental mechanisms of transcription. Here, the causal variant (star) is not the strongest GWAS signal, but rather a
variant in strong LD with the top effect located in an active enhancer region. (c) To gain insights into the biological processes leading to the phenotype, genes can
be prioritized and causal networks constructed. GWAS variants are generally common in the population and have smaller effect sizes (blue). Thus, the genes that
they impact are more likely to have a small effect on the phenotype as well ( peripheral genes). The genes on which many peripheral genes converge (core genes)





located up to 500 kb apart [8]. Consequently, any of them
could be the actual causal variant (figure 1b).
Second, the effects of non-coding causal variants can
be highly cell-type-, context- and disease-specific [9]. Non-
coding DNA contains regulatory regions—enhancers and
promoters—that can bind transcription factor (TF) proteins
and regulate gene expression [10]. Which enhancers and
promoters are used depends on the cell-type-specific
abundance of approximately 1600 human TFs and their
epigenetically regulated accessibility to a given regulatory
region [11]. Variants can disrupt the binding of any of these
TFs, resulting in changed enhancer or promoter activity.
This, in turn, affects gene expression [12] and cellular path-
ways [13]. Thus, the cell-type and tissue- or disease-specific
micro-environment greatly affect which variants, TFs, genes
and pathways are involved (figure 1). These complexities
make it difficult to understand how GWAS loci contribute
to their associated traits and have significantly hampered
the interpretation and application of GWAS results. To
address this, many different fine-mapping approaches have
been developed in the post-GWAS era with the aim of
identifying the important variants and genes and interpreting
their biological impact on diseases and traits [14–17].
Important to note is that to reduce fine-mapping complex-
ity, most approaches assume that only a single variant per
locus contributes to a trait. This is, however, not a proper
reflection of reality as multiple variants within a single
GWAS locus can have an effect on a single gene’s expression.
This can occur in one of two ways: either the effect of thevariants adds up in a linear way (additive effect) or an inter-
action between two or more variants is required to affect
gene expression (epistatic effect) [18,19]. Thus, multiple var-
iants may play a role in a single locus, either within a single
cell-type or in a context- and cell-type-specific manner [18].
This further complicates performing and interpreting fine-
mapping and gene prioritization approaches. For simplicity,
throughout this review, we continue to address variants that
affect gene regulation and pathways in association with a
GWAS trait in any way as causal, even though a collective of
smaller contributing effects acting in unison per locus may
be necessary to elicit a functional effect on a GWAS trait.
Here, we assess fine-mapping and gene prioritization
approaches that have been used to translate GWAS loci to a
functional understanding of the associated trait, while taking
cell-type- and disease-specific context into account. Specifi-
cally, we review the genetics of lower effect size common
variants identified through GWASs rather than high effect-size
Mendelian disease variants (figure 1c). Moreover, we discuss
the impact of the recent paradigm shift towards polygenic
models and how these can be used to aid in the identification
of gene networks that highlight core disease genes (figure 1c).2. Fine-mapping from the variant
perspective
Fine-mapping variants in GWAS loci require an understand-


































(a) mechanisms by which SNPs can influence enhancer activity





Figure 2. An illustrative depiction of a GWAS locus showing example mechanisms by which variant effects on enhancer activity and gene expression can be
detected. (a) Many trait-associated variants are shown with varying LD strength (scatterplot) when compared with the GWAS-identified marker variant (in
black). In this example, the causal variant is located in an allele-dependent active enhancer (C-allele, caQTL) as shown by the open chromatin regions of the
same locus (peak-density plot below the variant). The variant affects the TF binding site of the green TF with a strong binding preference for the C-allele, as
shown by the enhancer activity in the ‘transcription factor binding affinity’ box. In addition, using 3D interactions (grey arches connecting the gene, promoter
and enhancer), physical contact with the nearby ‘Gene X’ indicates the enhancer affects the gene’s expression. (b) To highlight cell-type-specific effects, the influence
of the causal variant is depicted in three cell types with varying TF availability. The mRNA expression of ‘gene X’ is stronger for the CC-genotype compared with the
GG-genotype because of the increased TF binding affinity to the green TF (as shown in a). This mRNA expression remains low but stable for the GG-genotype in all





contribute to a trait. Overcoming LD and identifying the
context-specific variants that are causal to a trait is imperative
for understanding disease mechanisms and confidently iden-
tifying which downstream genes and pathways are affected.
Many functional and computational (high-throughput) fine-
mapping methods have been developed and applied for
this purpose. Below we review several fine-mapping
methods according to their increasing ability to describe the
complex role of variants in GWAS traits and diseases.2.1. Identifying overlap with functional elements
The most straightforward fine-mapping approach is to
overlap GWAS variants in high LD with functional elements
such as promoters and enhancers (figure 2a). Currently, the
best resource for functional elements has been compiled
by the NIH Roadmap Epigenomics Mapping Consortium
[20] (electronic supplementary material, table S1), which




4to measure histone marks to determine the location of func-
tional elements in 127 different cell and tissue types [20,21].
Fine-mapping of GWAS variants from 21 autoimmune dis-
eases using the NIH Roadmap and similar data estimated
that approximately 60% of candidate causal variants map
to immune cell enhancers, and another approximately 8%
to promoters [12]. This was also reflected in the tissue-specific
enrichment of type 1 diabetes susceptibility variants in
lymphoid gene enhancers [22]. Moreover, candidate causal
variants were enriched in enhancers defined by the histone
mark H3K27ac in specific subsets of CD4+ T cells, CD8+
T cells and B cells [12]. This was also the case in another
study in monocytes, neutrophils and CD4+ T cells [23].
Other studies have also identified tissue-specific enrichments
of disease-associated variants via overlap with functional
elements, showing that this approach can help specify
which variants play a role in certain cell types [23,24].
Other ways of detecting regulatory regions that can be
used to fine-map GWAS variants are either based on
DNA accessibility, such as ATAC-seq [25] and DNase-seq
[26] (electronic supplementary material, table S2), or identify
the inherent transcriptional activity of enhancers and promo-
ters [27,28], such as GRO-seq [29], PRO-seq [30] and CAGE
[31] (electronic supplementary material, table S2). Collective
public databases using these techniques—like the NIH Road-
map consortium [20], ENCODE [32], FANTOM5 [33] and the
IHEC consortium [34]—are indispensable context-specific
resources (electronic supplementary material, table S1).
However, it appears to be more difficult than originally
anticipated to specify the exact location of regulatory regions
since all these methods show different sensitivities and
accuracies in the mapping of active regulatory regions [35].
Moreover, overlap of a variant with an active regulatory
region may not result in functional disruption of these
elements, and thus does not definitively point to causality.
This uncertainty limits the accuracy of fine-mapping through
overlap with functional elements and still leaves us with a
multitude of candidate causal variants.
2.2. Inferring allele-specific variant effects
In high-throughput methods such as ATAC-seq, the sequen-
cing reads containing a variant can be separated based on
its allele. The allele-specific abundance of sequencing reads
can then directly inform us about the functionality of this
variant on the open chromatin region. Variants that cause
allelic imbalance in regulatory regions are called chromatin
accessibility quantitative trait loci (caQTLs; figure 2a) [25,36].
Many caQTLs were identified in primary CD4+ T-cell
ATAC-seq peaks, and these showed a strong enrichment in
candidate causal autoimmune variants [36]. Similarly, the
existence of variants or histone-QTLs that affect regulatory
regions by altering enhancer-associated H3K27ac or
H3K4me1 histone peaks also implies that these variants
have an effect on cell-type-specific enhancer activity [23].
Due to their functional effect on DNA accessibility and
epigenetic marks, these variants are more likely to be
causal variants for GWAS traits.
Another mechanism by which non-coding GWAS variants
can have an allelic effect on gene expression is alternative
splicing of genes. GWAS-associated variants have the poten-
tial to induce cell-type-specific alternative splicing (sQTL) or
could affect trans-acting splicing regulation genes [37,38].This was shown in a genome-wide approach where 622
exons with intronic sQTLs were identified. One hundred
and ten of these exons harboured variants in LD with
GWAS marker variants [37]. In a more specific example,
the multiple sclerosis-associated PRKCA gene is seemingly
affected by an intronic sQTL that increases the expression
of a gene isoform more prone to nonsense-mediated decay,
thereby reducing the likely protective PRKCA mRNA levels
post-transcriptionally [39]. However, sQTLs appear to also
act through more complex mechanisms such as indirectly
through caQTLs [40], or by inducing alternative upstream
transcription start sites [41]. These and many other examples
[38] suggest that sQTLs may be an important but complex
mechanism by which GWAS-associated variants affect a trait.2.3. Identifying variants that disrupt underlying TF
binding sites
Further prioritization of variants in regulatory regions that
show allelic imbalances can be done by computational or
functional analysis of the underlying TF binding sites
(TFBS) or motifs. Regulatory regions consist of both very
strict and more degenerate DNA motifs [42] to which TFs
can bind in order to initiate local transcription (e.g. enhancer
RNAs) and regulate nearby or distant genes [10,27]. Variants
can change the TFBS, altering the binding affinity of the TF
and changing the activity of a regulatory region (figure 2a)
[18,43,44]. The specificity and location of potential TFBSs
have been collected for many cell types in large databases
such as JASPAR [45], FANTOM5 [33] and ENCODE [32]
(electronic supplementary material, table S1), mostly using
ChIP-seq and HT-SELEX [46] (electronic supplementary
material, table S2).
An enrichment of TFBS disruption by putatively causal
variants has been identified for 44 families of TFs [18]. For
TFs like AP-1 and the ETS TF-family, regulatory regions
containing these disrupted TFBSs also show effects on chro-
matin accessibility, indicating that the effect of variants on
TF binding affinity leads to caQTLs [18]. Similarly, upon
identification of nearly 9000 DNase-seq locations affected
by allelic imbalances, it was found that the alleles associated
with more accessible chromatin were also highly associated
with increased TF binding [43]. In a more specific case,
TFBS disruption analyses and in vitro confirmation by
ChIP-seq led to the identification of rs17293632 as a likely
causal SNP that increases Crohn’s disease risk by disrupting
an AP-1 TFBS [12]. Interestingly, this effect on AP-1 TFBSs
was stimulation-specific: H3K27ac peaks with affected AP-1
TFBSs were enriched in stimulated CD4+ T cells compared
with non-stimulated cells [12]. This highlights the importance
of context-specificity and the need for tissue- and disease-
relevant stimulations in experimental set-ups (figure 2b)
[12,47]. Finally, in a study of leukaemia patients, a small
DNA insertion resulting in a TFBS for MYB created an
enhancer near TAL1, which led to activation of this oncogene
and the onset of leukaemia [48]. Thus, decreased or increased
affinity of TFs due to genetic variants or small DNA changes
can have far-reaching effects.
Currently, only 10–20% of the potentially causal non-
coding GWAS variants defined by allelic imbalances within
a regulatory region can be shown to disrupt a known TFBS




5act through a different mechanism, or our understanding of
TF binding may still be insufficient [49]. One complicating
factor here is the potential cooperative binding of more
than one TF at an overlapping TFBS. Detection of these
cooperative binding motifs is currently being improved by
both biological methods (such as SELEX-seq [50]) and com-
putational methods, such as No Read Left Behind (NRLB)
[44]) (electronic supplementary material, table S3). A striking
example of context-specific cooperative binding of TFs is
illustrated by an increased TFBS enrichment of p300, RBPJ
and NF-kB in risk loci of GWAS traits as a consequence of
the presence of Epstein–Barr virus (EBV) EBNA2 protein
[51]. In this study, ChIP-seq data from EBV-transformed
B-cell lines were used, together with the RELI algorithm
(electronic supplementary material, table S3), to systemati-
cally estimate the enrichment of variants in TFBS [51]. In
six out of the seven autoimmune disorders tested, RELI
identified that 130 out of 1953 candidate causal variants
[12] overlapped with EBNA2 binding sites in B-cell lines
identified by ChIP-seq [51]. Interestingly, many autoimmune
diseases, including coeliac disease and multiple sclerosis
[52,53], are thought to be partially triggered by viral infec-
tions, suggesting that variants may only be causal when
viral factors are also present. Moreover, TF motifs can be
highly degenerate, and a small change in TF binding affinity
can induce a subtle dosage effect on the activity of a regulat-
ory region [44]. While this effect may be subtle, downstream
genes could be affected sufficiently [44] to induce or affect a
trait. Thus, a better understanding of how TF binding affinity
to DNA motifs is mediated is necessary to comprehend how
variants affect the functionality of a regulatory region.2.4. Fine-mapping by detection of regulatory region
activity
A more immediate fine-mapping approach is to directly
measure the effect a variant can have on the strength of a
regulatory region. Active promoters and enhancers have tran-
scription start sites (TSSs), and the activity of an enhancer or
promoter is directly correlated with the active transcription
from these TSSs [27]. However, some promoter RNAs, and
most enhancer RNAs, are very short-lived, making them dif-
ficult to detect with most RNA sequencing methods [10,27].
CAGE (electronic supplementary material, table S2) does
allow for the identification of exact TSS locations, as well as
expression levels of genes, by sequencing 50-capped tran-
scripts regardless of their stability [30]. CAGE has identified
promoter and enhancer effects, and showed that 52% of
the effects observed in promoter regions were in secondary
CAGE peaks, highlighting that genes can have multiple
active promoters depending on the genotype [54]. CAGE
QTLs have been observed for loci associated with systemic
lupus erythematous (SLE) and inflammatory bowel disorder
[54], supporting their relevance in immune disease.
Reporter-plasmid assays can also be applied to directly
measure the effects of variants on enhancer or promoter
TSS activity by moving variant-containing DNA fragments
from their natural environment to a plasmid and transfecting
these into a cell type of interest. The most traditional reporter-
plasmid assay, the luciferase assay (electronic supplementary
material, table S2), was used to confirm a functional effect of
rs1421085, which is associated with obesity risk, by showingthat the risk-allele induces an increase in enhancer activity [55].
However, high-throughput reporter assay methods with high
resolution are required to fine-map all potentially causal
variants within entire GWAS loci based on regulatory
region activity.
One such method, the massively parallel reporter assay
(MPRA; electronic supplementary material, table S2), can
test over 30 000 candidate variants by synthetically creating
180 bp DNA fragments containing both alleles of a variant
with a unique barcode and integrating these into GFP-
reporter plasmids that are subsequently transfected into
different cell lines [56]. An MPRA was used to identify the
expression of 12% (3432) of the 30 000 candidate DNA
fragments in three cell lines, with 842 showing allelic
imbalances caused by SNPs. Indeed, 53 of these SNPs had
previously been associated with GWAS traits [56]. Similar
high-throughput fine-mapping methods that use patient-
derived DNA instead of synthetically generated DNA
sequences are STARR-seq [57] and SuRE [58] (electronic
supplementary material, table S2). Using a whole-genome
approach, the SuRE method managed to screen 5.9 million
SNPs in the K562 red blood cell line, identifying over
30 000 SNPs that affect regulatory regions and allowing for
in-depth fine-mapping of SNPs for 36 blood-cell-related
GWAS traits [59]. Follow-up research on these reporter
assays has identified a causal SNP (rs9283753) in ankylosing
spondylitis [56] and another (rs4572196) in potentially up to
11 red blood cell traits [59]. Despite the obvious advantages
of high-throughput fine-mapping screens, a major drawback
is that these methods are usually applied in cancer or EBV-
transformed cell lines. These cell lines can be significantly
different from trait-specific tissue-derived cell types [60]
and have often accumulated many somatic mutations as a
consequence of years of culturing [61]. Thus, the wrong variants
may be identified as causal because the relevant cell-type and
context-specific effects have not been considered [62].2.5. From causal variant to gene using the 3D
interactome
When a causal variant has been identified, the gene
expression effects of that variant can be directly assessed by
mapping the necessary physical interaction of the regulatory
region it affects with its target genes (figure 2a) [63,64]. For
example, H3K27ac regions containing autoimmune-disease-
prioritized variants were linked to the TSS of genes using
HiChIP (electronic supplementary material, table S2) and
shown to contain cell-type-specific interactions between the
TSS of the IL2 gene and rs7664452 in Th17 cells and between
rs2300604 and target gene BATF in memory T cells [63].
Interestingly, for 684 autoimmune-disease-associated variants
assessed with HiChIP, 2597 gene–variant interactions were
identified, indicating that autoimmune disease variants can
regulate a multitude of genes. Moreover, only 14% (367) of
these gene–variant interactions were with the gene closest
to the variant [63]. Another example of a long-range
interaction of a causal variant is that of the previously men-
tioned rs1421085, which is associated with obesity risk and
located in an intron of FTO. TFBS disruption analyses have
shown that rs1421085 disrupts the ARID5B TF binding
motif and affects the activity of an enhancer that regulates




6the initially expected co-localized FTO gene itself [55,65].
Thus, fine-mapping and interaction analysis has identified
additional causal genes in this obesity-associated risk locus.
Hi-C (electronic supplementary material, table S2) is
another high-throughput method for identifying specific
promoter and enhancer gene interactions [19,66–68]. For
example, Hi-C was used to prioritize four rheumatoid
arthritis genes by overlapping promoter–gene interactions
of various primary immune cells with rheumatoid arthritis
GWAS variants [19]. Another study analysed Hi-C datasets
of 14 primary human tissues and showed that frequently
interacting regions (FIREs) are enriched for disease-
associated GWAS variants [68]. However, the resolution
limitations of Hi-C and other interaction data make it difficult
to precisely pin-point the causal variant within a regulatory
region [63,64,68]. In addition, cell-type and environmental
effects influence regulatory region interactions with genes,
as shown by the fact that 38.8% of FIREs were identified in
only one tissue or cell type [68]. Thus, multiple strategies as
described here and collected in databases such as the Enhan-
cerAtlas2.0 [69] (electronic supplementary material, table S1)
should be combined to confidently fine-map causal variants
and link them to genes that play a role in GWAS traits.3. Gene prioritization using GWAS traits
Traditional fine-mapping approaches focus on identifying
the causal variants that affect a trait of interest. While very
important, knowing which variants are causal does not
identify the downstream effects of the variant on the trait.
One way to gain such insights is by identifying the genes
that are affected by each GWAS locus. Moreover, if the
causal genes affected by a locus are known, this can reduce
the credible set of potentially causal variants. Recent efforts
in systems biology have focused on identifying such causal
genes and their downstream effects.
3.1. Gene prioritization using expression quantitative
trait loci
A more comprehensive approach to identifying the genes
affected by a GWAS locus is through the use of quantitative
trait loci (QTL; figure 3a). While caQTLs are often indicative
of a causal variant or regulatory region, a specific subset of
QTLs called expression QTLs (eQTL) can be used to identify
the genes affected by a GWAS locus [70–72]. The simplest
way to perform gene prioritization using eQTL analysis is
simply to overlap the marker variant of a GWAS locus with
the top eQTL variant. An example of this is an SLE risk
variant that is also a cis-eQTL for the TF IKF1. The eQTL
on IKF1 affected the transcription of 10 genes in trans that
are all regulated by IKF1 [70], highlighting this gene as a
likely candidate causal gene for SLE. Additionally, these
types of effects can be context-specific, as was shown for a
cis-eQTL on TLR1 after stimulation of peripheral blood
mononuclear cells (PBMCs) with Escherichia coli [73]. This
cis-eQTL was also a strong trans regulator of the E. coli-
induced response network, regulating another 105 genes
[73], showing that an eQTL can strongly influence the
immune response to pathogens.
However, the top eQTL variant might not always be the
same as, or in LD with, the top GWAS marker variant dueto noise in the eQTL data [74] or to multiple causal effects
on a gene or disease in a locus [75]. As a result, many statisti-
cal frameworks have been created to give more accurate
estimates of overlap or causality between a GWAS locus
and a QTL locus, including FUMA [76], COLOC [77] and
Mendelian randomization (MR; electronic supplementary
material, table S3). The latter is commonly used to estimate
causality between GWAS and QTL profiles [78–84] and has
been successfully applied to identify genes causally linked
with complex traits [3,79–81]. For example, MR studies
were able to identify a causal role for SORT1 on cholesterol
levels [79,81], a role which has been experimentally validated
[85]. Still, MR can be challenging as multiple variants in LD
can affect the same gene (linkage), and several genes can be
affected by the same causal variants (pleiotropy) [70,73,86].
More recent work on MR has focused on more accurately
controlling for pleiotropy and linkage [79,81,82,84]. Indepen-
dent variant selection for MR is currently done by either
LD-based clumping or some form of stepwise regression
using tools like GCTA’s COJO [75] (electronic supplementary
material, table S3), which only select for independence and
not causality. Accurate fine-mapping can potentially help
these efforts by improving the independent variant selection
for MR since fine-mapping can reveal the true causal variants
independent of linkage.
Recently, it has been suggested that approximately 70% of
the heritability in mRNA expression is due to trans-eQTLs
[87,88], which highlights the importance of trans-eQTL
relationships. While trans-eQTLs have the potential to further
our understanding of complex traits, the multiple testing
burden is very large due to the large number of comparisons
that have to be made when doing genome-wide trans-eQTL
mapping (in the worst case, millions of variants times
approx. 60 000 genes) [70,72]. Therefore, many eQTL studies
opt to only map cis-eQTL effects genome-wide, as this
dramatically reduces the number of comparisons that have
to be made [70–72,74]. Another approach is to limit the
number of comparisons by only mapping trans effects for
a predefined subset of variants or genes [70,72,73,86].
However, since a full trans-eQTL mapping dataset is rarely
available, overlap between trans-acting genes and GWAS
loci will be missed.
An additional challenge with QTL-based gene prioriti-
zation approaches lies in the context-specificity of the
QTL data used, as different tissues, cell types, time
points and stimulation conditions can induce many differ-
ent expression patterns and different interactions with the
variants in a GWAS locus [23,73,89–92]. Consequently, the
QTL information that is available might not be informative
for the trait under study. This is especially challenging
when studying traits that are present in a tissue other
than blood, as is the case for neurological disorders
[93,94], because sufficiently powerful cell-type- or context-
specific QTL studies are usually not available. However,
with the advent of single-cell RNA sequencing (scRNAseq)
and the increasing availability of large-scale datasets for
tissues other than blood, some of these challenges are
being overcome [70,72,90,91]. scRNAseq (electronic sup-
plementary material, table S2) allows for high-throughput
eQTL analysis in individual cell types instead of a bulk
population, as shown for PBMCs [90]. This allows for an
increase in resolution and can help to assess only the


















Figure 3. Aspects of fine-mapping genes from GWAS loci. (a) Using eQTLs (dark blue) and CRISPRi/a-based assays, GWAS loci can be linked to genes when using the
correct context. (b) Not every relationship between genetics and expression can be described additively. Epistatic effects (dark red) describe a relationship where two
(or more) mutations are needed to arrive at the phenotype. (c) Using co-expression, regulatory relationships between genes can be quantified, but the specific role
of genetics in these relationships is unknown. (d ) Using PGSs, the joint effects of GWAS loci can be assessed, sacrificing resolution to obtain higher-level insights into
the pathways affected by the genetics associated with a phenotype. (e) When assessed at single-cell resolution, the total network can be deconstructed into the cell-
type relevant components. Affected cells can subsequently display an altered interaction with other cells within a tissue or individual, leading to a changed tissue- or





TSPAN13 and ZNF414, which were only present in CD4+ T
cells and not in bulk or other specifically assessed cell
types [90]. Consortia that are amassing single-cell data
at a large scale in many different tissues—like the
Human Cell Atlas [95], Single-cell eQTLgen [96] and the
LifeTime consortium [97] (electronic supplementary
material, table S1)—will facilitate the use of single-cell
sequencing data for traits where bulk RNA-seq obtained
from blood is not informative.3.2. Identifying downstream effects of GWAS loci using
other QTLs
Beyond gene-expression-based eQTL, a plethora of other
QTL types exist that affect the abundance of proteins
(pQTL) [98,99], metabolites (mQTL) [100], DNA methylation(meQTL) [101], microbiota (miQTL) [102] and cells (cell-count
or ccQTL) [103,104]. Naturally, these can all be overlapped
with GWAS loci to obtain insights into their pathology.
For example, the ex vivo cytokine response to stimulation
has been shown to have strong genetic regulators [99].
Interestingly, all the associated effects found were trans (i.e.
not in proximity to the cytokine genes), suggesting that the
release of cytokines is controlled by genes in the receptor’s
pathways rather than being directly controlled by the
mRNA levels of the cytokine. Moreover, context-specificity
is important, as QTLs affecting cytokines from T cells were
found to be enriched in autoimmune GWAS loci, whereas
QTLs affecting cytokines from monocytes were more
enriched in infectious-disease-associated loci [99]. Thus, the
effects of genetics on traits should not only be studied at
the level of gene expression, but also at levels more directly




83.3. Functional approaches to mapping genetic effects
on expression
While eQTL analysis provides invaluable insights into the
genes that affect a trait or disease, context- and cell-type-
specific biases in the expression data and LD structure in
GWAS loci cause potential errors in gene prioritization.
With the recent introduction of CRISPR/Cas9-based screens
[105] (electronic supplementary material, table S2), it is
now possible to functionally validate eQTL effects in a
high-throughput manner independent of LD structure and
in a cell-type relevant to the trait of interest.
CRISPR-based assays use guide RNAs to bind specific
regions of the genome and either activate (CRISPRa) or
interfere (CRISPRi) with the transcription of genes or
enhancers [106]. Recent advances in both scRNAseq and
CRISPRi/a have facilitated methodologies that evaluate
enhancer effects on genes in single cells [107]. For example,
a recent effort evaluated the effects of 5920 candidate
enhancers on gene expression using CRISPRi [107].
Strikingly, 664 showed a significant effect on gene
expression in K562 cells. Thus, CRISPRi-based assays are
capable of identifying enhancer–gene pairs in a high-
throughput manner. However, as only approximately 10%
of candidate enhancers were actually found to affect gene
expression, identifying which enhancers are active based
on already available data might not always be straightfor-
ward, even for a very well-characterized cell line such as
K562 [20,32,34,58,59].
In addition to mapping active enhancer gene pairs,
CRISPRi/a-based assays can be used to identify epistatic
interactions between genes and to generate gene networks
based on changes in co-expression in perturbed versus
non-perturbed cells (figure 3b). Genes that are strongly
co-expressed are likely to be regulated by a shared mechan-
ism [86]. Therefore, identifying such genes can help
reveal the gene network that leads to a disease-associated
trait [94,108,109]. Indeed, a CRISPRi screen that targeted
12 TFs, chromatin modifying factors and non-coding
RNAs was able to identify epistatic effects in cells per-
turbed by two guide RNAs [110]. In these cells,
chromatin accessibility remained relatively stable in loci
associated with autoimmune disease in cells with one
perturbed TF. However, significant changes were observed
when evaluating the chromatin accessibility for the same
loci in cells also perturbed for NFKB1. This again high-
lights the importance of taking the entire context of a
trait into account when fine-mapping or interpreting the
role of a GWAS locus.
A major drawback of the majority of CRISPRi/a screens is
that they are very laborious and therefore usually performed
in easily manipulated, but also highly modified, cancer
cell lines [61]. Fortunately, recent studies have shown that
CRISPRi screens can be applied to primary T cells [111,112].
This, while challenging, needs to be extended to other tissues
and model systems. These studies will greatly assist variant,
regulatory region and gene fine-mapping efforts because
they directly identify the active enhancer–gene pairs and
the downstream gene network affected in specific cell
types. In addition, future work could focus on performing
CRISPRi/a screens in patient-derived cells that contain
relevant risk genotypes to fully reach variant-level resolution.3.4. Mapping gene–gene regulatory interactions using
population data
Co-expression can also be modelled based on inter-individual
variation in expression, which can be used to prioritize
disease genes and make inferences about the downstream
consequences of diseases (figure 3c) [94,108,109,113]. For
example, DEPICT (electronic supplementary material,
table S3) integrates gene co-regulation with GWAS data to
provide likely causal genes and pathways relevant for the
trait [113]. Moreover, the GADO tool (electronic supplemen-
tary material, table S3) correctly identified causal genes in
41% of a cohort of 83 patients with varying Mendelian
disorders, and prioritized several novel causal candidate
genes by combining trait-specific gene sets with a co-
expression network [109]. Finally, eMAGMA (electronic
supplementary material, table S3) used co-expression together
with tissue-specific eQTLs in brain regions to prioritize 99
candidate causal genes for major depressive disorder [94].
These co-expression modules were enriched in brain regions
but not in whole-blood, highlighting the tissue-specific
nature of the co-expression networks [94].
Population-based co-expression networks describe the
relationships between genes through both genetics and
environment. Consequently, based on the co-expression
alone, it is not possible to separate which part of the co-
expression is due to genetics. Therefore, these networks
have limited use for fine-mapping causal variants and are
mainly used to identify genes and pathways affected by
GWAS loci after gene prioritizations have been made. In
addition, co-expression networks are not directed [108].
Genetic information of the individuals used to generate the
co-expression network would solve this issue, as the genetic
and environmental components could be separated and
directionality could be added into the network [108],
although this is not a trivial task. Fine-mapping would
be of great value in modelling the genetic component of the
network by facilitating the selection of true causal variants.
3.5. Fine-mapping under the omnigenic model
As discussed throughout this review, it is becoming increas-
ingly clear that complex traits are highly polygenic and that
many variants can deregulate cis- and trans-acting factors in a
variety of ways (figure 2a). In the light of this, Boyle et al. [87]
proposed an omnigenic model for complex traits in which
each gene that is expressed in the cell will have an effect on
the trait or disease in some way (figure 1c) [87,88]. For example,
height is so polygenic that most 100 kb genomic windows seem
to contribute to explaining its variance. Given that the effect
sizes of the individual variant are getting so small, it raises
the question: what does the causality of the individual variant
mean in a complex trait [87,88,114]? If the omnigenic model
is true, it presents a major challenge for fine-mapping GWAS
loci, particularly for the interpretation of the downstream con-
sequences as the complexity of genetic effects on traits will
only increase. In addition, current functional assays may not
be suited to model the small and subtle variant effects and
gene–gene or gene–environment interactions observed in
population studies using millions of individuals.
Instead, the complete GWAS signal from all loci




9score (PGS) that describes an individual’s genetic pre-
disposition for the given trait. In its most basic form, a PGS
constitutes the linear combination of all independent risk
genotypes weighted by the GWAS effect size, but many
more sophisticated methods exist (figure 3d ) [115–117]. The
PGS for a trait can be associated with the expression level
of genes (and proteins) in a population [72,118]. If there are
strong correlations, GWAS loci together, as represented by the
PGS, are jointly influencing these genes. These genes probably
represent core genes in a disease-associated co-expression net-
work. Although PGSs have issues when it comes to broad
applicability across populations [119], they can be a useful
abstraction layer to make sense of a polygenic trait.
Given we are becoming aware of the likely polygenic and
even omnigenic nature of traits, fine-mapping the individual
GWAS locus seems like an impossible task. However, with
current approaches the stronger, and arguably more impor-
tant, genetic effects associated with traits and diseases can
be elucidated [70,72,73]. Moreover, by using abstraction
layers such as PGS, inferences can be made about the joint
consequences of these effects [72]. Indeed, the genes and
pathways associated with stronger or joint genetic effects
are more likely candidates for drug interventions [120] (elec-
tronic supplementary material, table S1). Although we might
never fully comprehend all the tiny effects and interactions
underlying a trait, we will probably see an increase in
clever ways to arrive at the interpretable biological mechanisms
behind traits.4. Future perspectives
We have reviewed recent high-throughput GWAS fine-mapping
approaches that can identify variants and genes causal for atrait or disease. The complexity and uncertainty present in
aspects of these approaches illustrates that a single approach
does not suffice to grasp the full cause and effect of candidate
variants and genes. In addition, while large datasets, mostly
in blood, have identified many potentially causal variants
and genes associated with traits, these candidates need to
be refined and validated using tissue- and cell-type-specific
resources in combination with trait-specific environmental fac-
tors to recapitulate the true biological state of each trait as
closely as possible. An additional challenge lies in translating
these disease genes into clinical practice, as prioritized genes
might not be existing, nor practical, drug targets.
Despite these challenges, we believe that combining the
use of patient-derived material, with methods that find regu-
latory regions and their downstream genes will aid drug
target identification for complex diseases. In addition, this
knowledge could be used to generate prediction models
that aid in the fast and non-invasive identification of trait-
specific variants and genes in the general population. This
will form the foundation of our understanding of complex
traits, aid drug development and will allow tailored precision
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